论文部分内容阅读
造血器官恶性肿瘤患者治疗前粒细胞减少,自身免疫能力下降。对此类患者施行抗肿瘤疗法,其免疫能力会进一步降低。因此,这类合并感染症容易恶化使患者致命。故在感染早期用杀菌抗生素进行高效的化学疗法是至关重要的。舒巴克坦/头孢哌酮(SBT/CPZ)是β-内酰胺酶抑制剂和头孢菌素以1:1配比的复合制剂,该制剂对高度β-内酰胺酶产生菌显示抗菌活性。基础疾病患者41例、男18例、女23例,年龄17—82岁。基础疾病为:白血病23例、恶性淋巴瘤9例、骨髓异常综合症5例、骨髓纤维症1例、障碍性贫血2例、无颗粒细胞症1例。感染患者治疗病例为44例;肺炎或上
Hematopoietic malignancies in patients with pre-treatment neutropenia, decreased autoimmune ability. Anti-tumor therapy for such patients, its immune capacity will be further reduced. Therefore, such a combination of infectious diseases easily deteriorate the patient deadly. Therefore, in the early stages of infection with bactericidal antibiotics for efficient chemotherapy is crucial. Sulbactam / cefoperazone (SBT / CPZ) is a complex preparation of 1: 1 ratio of β-lactamase inhibitor and cephalosporin, which shows antibacterial activity against highly β-lactamase-producing bacteria. 41 cases of underlying diseases, 18 males and 23 females, aged 17-82 years. The underlying diseases were: leukemia in 23 cases, malignant lymphoma in 9 cases, 5 cases of myelodysplastic syndrome, 1 case of myelofibrosis, 2 cases of aplastic anemia, 1 case of non-granulocytic disease. Infected patients were treated in 44 cases; pneumonia or upper